Table 3.

Probability of survival three years subsequent to diagnosis, by prevalent tumor status and stratified by melanoma stage at the time of diagnosis.

	Overall survival		Melanoma-specific survival
Variable	3-year survival [95% CI]	p-value a	3-year survival [95% CI]	p-value a
All patients (n = 2978)	86.6% [85.3% - 87.9%]	–	93.2% [92.2% - 94.2%]	–
Prevalent tumors		<0.001		0.497
Absent	87.2% [85.9% - 88.5%]		93.3% [92.3% - 94.3%]
Present	74.3% [66.8% - 82.6%]		90.6% [85.0% - 96.5%]
Stage I and II patients (n = 2476)
Prevalent tumors		<0.001		0.008
Absent	93.6% [92.5% - 94.7%]		98.4% [97.8% - 99.0%]
Present	79.9% [72.0% - 88.7%]		93.4% [87.7% - 99.4%]
Stage III and IV patients (n = 393)
Prevalent tumors		0.556		0.377
Absent	58.4% [53.3% - 63.9%]		63.9% [58.8% - 69.4%]
Present	52.2% [35.3% - 77.2%]		74.4% [57.1% - 97.0%]

^alog-rank test.